CERo Therapeutics Holdings, Inc. Common Stock - Asset Resilience Ratio
CERo Therapeutics Holdings, Inc. Common Stock (CERO) has an Asset Resilience Ratio of 8.06% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (None–None)
This chart shows how CERo Therapeutics Holdings, Inc. Common Stock's Asset Resilience Ratio has changed over time. See financial agility of CERo Therapeutics Holdings, Inc. Common to measure the company's free cash flow as a share of total liabilities.
Liquid Assets Composition Over Time
This chart breaks down CERo Therapeutics Holdings, Inc. Common Stock's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see CERo Therapeutics Holdings, Inc. Common stock valuation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $500.00K | 8.06% |
| Total Liquid Assets | $500.00K | 8.06% |
Asset Resilience Insights
- Limited Liquidity: CERo Therapeutics Holdings, Inc. Common Stock maintains only 8.06% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
CERo Therapeutics Holdings, Inc. Common Stock Industry Peers by Asset Resilience Ratio
Compare CERo Therapeutics Holdings, Inc. Common Stock's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Prostemics Co. Ltd
KQ:203690 |
Biotechnology | 0.31% |
|
ORUM
KQ:475830 |
Biotechnology | 82.74% |
|
TELIX Pharmaceuticals Ltd
AU:TLX |
Biotechnology | 32.29% |
|
TG Therapeutics Inc
NASDAQ:TGTX |
Biotechnology | 4.72% |
|
Green Cross Holdings Preference Shares
KO:005257 |
Biotechnology | 0.50% |
|
Rocket Pharmaceuticals Inc
NASDAQ:RCKT |
Biotechnology | 33.70% |
|
NEWRON PHARMACEUT. EO-20
XETRA:NP5 |
Biotechnology | 41.67% |
|
Cybin Inc
NEO:CYBN |
Biotechnology | 0.21% |
Annual Asset Resilience Ratio for CERo Therapeutics Holdings, Inc. Common Stock (None–None)
The table below shows the annual Asset Resilience Ratio data for CERo Therapeutics Holdings, Inc. Common Stock.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| No yearly data available. | ||||
About CERo Therapeutics Holdings, Inc. Common Stock
CERo Therapeutics Holdings, Inc., an immunotherapy company, engages in the development of engineered T cell therapeutics for the treatment of cancer. The company's lead development candidate is CER-1236, an autologous T cell therapy candidate for the treatment of hematologic malignancies and solid tumors. The company was incorporated in 2021 and is based in South San Francisco, California.